---
title: "Genmab Advances Share Buy-back Program with Significant Transactions"
description: "Genmab A/S has updated its share buy-back program initiated on March 25, 2025, aiming to repurchase up to 2.2 million shares. As of April 11, 2025, 1,083,902 shares have been repurchased, enhancing th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/235913386.md"
published_at: "2025-04-14T16:57:31.000Z"
---

# Genmab Advances Share Buy-back Program with Significant Transactions

> Genmab A/S has updated its share buy-back program initiated on March 25, 2025, aiming to repurchase up to 2.2 million shares. As of April 11, 2025, 1,083,902 shares have been repurchased, enhancing the company's capital structure and commitment to shareholders. Spark's AI Analyst rates GMAB as Outperform, citing strong financial performance and a robust pipeline, despite a short-term downward trend. Genmab, based in Copenhagen, focuses on innovative antibody therapeutics and aims to transform cancer treatment by 2030.

Genmab ( (GMAB) ) has provided an update.

On April 14, 2025, Genmab A/S announced the progress of its share buy-back program, initiated on March 25, 2025, to repurchase up to 2.2 million shares. The program, intended to reduce capital and fulfill commitments under the Restricted Stock Unit program, saw transactions from April 7 to April 11, 2025, accumulating a total of 1,083,902 shares repurchased so far. This strategic move is expected to impact Genmab’s capital structure positively and reflects the company’s commitment to its shareholders.

**Spark’s Take on GMAB Stock**

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab demonstrates strong financial performance with excellent revenue growth and profitability. The company’s strategic investments and robust pipeline support long-term prospects. While technical indicators show a short-term downward trend, the stock might rebound due to its underlying strength. Valuation appears reasonable, supporting a positive outlook.

To see Spark’s full report on GMAB stock, click here.

**More about Genmab**

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics. Established in 1999, the company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.

**YTD Price Performance:** -10.43%

**Average Trading Volume:** 1,652,152

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $11.87B

Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.

## Trending Articles:

-   BP Stock (NYSE:BP) Strikes it Rich in the Gulf of America
-   Potential Alaska Resurgence in LNG Does Not Balk TC Energy Stock (TSE:TRP)
-   NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [GMAB.US - Genmab A/S](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Genmab Discloses CFO Insider Share Sale Under EU Market Abuse Rules | Genmab A/S disclosed an insider share sale by CFO Anthony Pagano, who sold 1,100 shares at an average price of DKK 1,810 | [Link](https://longbridge.com/en/news/276478570.md) |
| Genmab Announces Initiation of Share Buy-Back Program | Genmab A/S :GENMAB - TO REPURCHASE UP TO 342,130 SHARES FOR 725 MILLION DKK | [Link](https://longbridge.com/en/news/276163502.md) |
| Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target | Jefferies analyst Benjamin Jackson maintained a Buy rating on Genmab A/S with a price target of DKK 2,650. He cites a st | [Link](https://longbridge.com/en/news/276089857.md) |
| A Glimpse Into The Expert Outlook On Genmab Through 4 Analysts | 4 analysts have provided varied opinions on Genmab (NASDAQ:GMAB) recently, with ratings ranging from bullish to bearish. | [Link](https://longbridge.com/en/news/276162396.md) |
| A Peek at Genmab's Future Earnings | Genmab (NASDAQ:GMAB) will report its quarterly earnings on February 17, 2026, with analysts estimating an EPS of $0.44.  | [Link](https://longbridge.com/en/news/276064631.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.